Glycovirology Scientific Publications

featured
Galectin approach to lower covid transmission - Drug Development for clinical useGalectin approach to lower covid transmission - Drug Development for clinical use
SARS-CoV-2 S glycoprotein binding to multiple host receptors enables cell entry and infectionSARS-CoV-2 S glycoprotein binding to multiple host receptors enables cell entry and infection
Identification of lectin receptors for conserved SARS-CoV-2 glycosylation sitesIdentification of lectin receptors for conserved SARS-CoV-2 glycosylation sites
Targeted protein S-nitrosylation of ACE2 inhibits SARS-CoV-2 infectionTargeted protein S-nitrosylation of ACE2 inhibits SARS-CoV-2 infection
Cellular and Molecular Mechanism of Pulmonary Fibrosis Post-COVID-19: Focus on Galectin-1, -3, -8, -9Cellular and Molecular Mechanism of Pulmonary Fibrosis Post-COVID-19: Focus on Galectin-1, -3, -8, -9
The Two Nobel Prize InvestmentThe Two Nobel Prize Investment
Galectin Antagonist use in Mild Cases of SARS-CoV-2: Pilot Feasibility Randomised, Open Label, Controlled TrialGalectin Antagonist use in Mild Cases of SARS-CoV-2: Pilot Feasibility Randomised, Open Label, Controlled Trial
go back

Sign up for
BioXyTran Updates

Site
Terms of Sale
Terms of Use
Privacy Policy
Careers
233 Needham Street
Suite 300
Newton, MA, 02464
617-454-1199
info@bioxytraninc.com
Follow us on Twitter
Follow us on Facebook
Follow us on Instagram
Follow us on LinkedIn
All statements and expressions are the sole opinion of the editor and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements". Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as "expects", "will", "anticipates", "estimates", "believes", or by statements indicating certain actions "may", "could", "should" or "might" occur.
© 2019 BioXyTran Inc.. All Rights Reserved